Affiliations 

  • 1 Biosensors Laboratory, Department of Biomedical Engineering, Faculty of Engineering, Mahidol University, Nakhon Pathom, 73170, Thailand
  • 2 Center of Research and Development of Medical Diagnosis Laboratories, Faculty of Associated Medical Sciences, KhonKaen University, KhonKaen, 40002, Thailand; Center for Innovation and Standard for Medical Technology and Physical Therapy (CISMaP), KhonKaen University, KhonKaen, 40002, Thailand
  • 3 Pilot Plant Development and Training Institute (PDTI), King Mongkut's University of Technology Thonburi, Bangkok, 10150, Thailand
  • 4 Department of Oral Medicine and Periodontology, Faculty of Dentistry, Mahidol University, Bangkok, 10400, Thailand
  • 5 Faculty of Applied Sciences, AIMST University, 08100, Semeling, Kedah, Malaysia; Centre of Excellence for Omics-Driven Computational Biodiscovery (ComBio), AIMST University, Bedong, 08100, Malaysia
  • 6 Biosensors Laboratory, Department of Biomedical Engineering, Faculty of Engineering, Mahidol University, Nakhon Pathom, 73170, Thailand. Electronic address: benchaporn.ler@mahidol.ac.th
Talanta, 2024 Mar 01;269:125495.
PMID: 38043336 DOI: 10.1016/j.talanta.2023.125495

Abstract

Cervical cancer emerges as the third most prevalent types of malignancy among women on a global scale. Cervical cancer is significantly associated with the persistent infection of human papillomavirus (HPV) type 16. The process of diagnosing is crucial in order to prevent the progression of a condition into a malignant state. The early detection of cervical cancer through initial stage screening is of the utmost significance in both the prevention and effective management of this disease. The present detection methodology is dependent on quantitative polymerase chain reaction (qPCR), which necessitates the use of a costly heat cycler instrument. In this study, we report the development of an electrochemical DNA biosensor integrated with an isothermal recombinase polymerase amplification (RPA) reaction for the detection and identification of the high-risk HPV-16 genotype. The electrochemical biosensor exhibited a high degree of specificity and sensitivity, as evidenced by its limit of detection (LOD) of 0.23 copies/μL of HPV-16 DNA. The validity of this electrochemical platform was confirmed through the analysis of 40 cervical tissues samples, and the findings were consistent with those obtained through polymerase chain reaction (PCR) testing. Our straightforward electrochemical detection technology and quick turnaround time at 75 min make the assay suitable for point-of-care testing in low-resource settings.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.